The Emergence of Linezolid Resistance Among Enterococci in Intestinal Microbiota of Treated Patients is Unrelated to Individual Pharmacokinetic Characteristics

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2014 Feb 26

PMID 24566182

Citations 5

Authors

N Bourgeois-Nicolaos

T T Nguyen

G Defrance

L Massias

L Alavoine

A Lefort

V Noel

E Senneville

F Doucet-Populaire

F Mentre

A Andremont

X Duval

Affiliations

Soon will be listed here.

Abstract

Linezolid is an antimicrobial agent for the treatment of multiresistant Gram-positive infections. We assessed the impact of linezolid on the microbiota and the emergence of resistance and investigated its relationship with plasma pharmacokinetics of the antibiotic. Twenty-eight patients were treated for the first time with linezolid administered orally (n = 17) or parenterally (n = 11) at 600 mg twice a day. Linezolid plasma pharmacokinetic analysis was performed on day 7. Colonization by fecal enterococci, pharyngeal streptococci, and nasal staphylococci were assessed using selective media with or without supplemental linezolid. The resistance to linezolid was characterized. The treatment led to a decrease of enterococci, staphylococci, and streptococci in the fecal (P = 0.03), nasal, and pharyngeal (P < 0.01) microbiotas. The appearance of resistant strains was observed only in enterococci from the fecal microbiota between the 7th and 21st days of treatment in four patients (14.3%). The resistance was mainly due for the first time to the mutation G2447T in the 23S rRNA gene. No pharmacokinetic parameters were significantly different between the patients, regardless of the appearance of resistance. The emergence of linezolid resistance during treatment was observed only in the intestinal microbiota and unrelated to pharmacokinetic parameters. However, colonization by Gram-positive bacteria was reduced as a result of treatment in all microbiotas.

Citing Articles

The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment.

Alvarado-Pena N, Galeana-Cadena D, Gomez-Garcia I, Mainero X, Silva-Herzog E Front Microbiol. 2023; 14:1237998.

PMID: 38029121 PMC: 10643882. DOI: 10.3389/fmicb.2023.1237998.

Resistance towards Critically Important Antimicrobials among and in Poultry Farm Environments in Selangor, Malaysia.

Rajendiran S, Veloo Y, Thahir S, Shaharudin R Antibiotics (Basel). 2022; 11(8).

PMID: 36009987 PMC: 9405032. DOI: 10.3390/antibiotics11081118.

A mutation in the glycosyltransferase gene lafB causes daptomycin hypersusceptibility in Enterococcus faecium.

Mello S, Van Tyne D, Lebreton F, Silva S, Nogueira M, Gilmore M J Antimicrob Chemother. 2019; 75(1):36-45.

PMID: 31586422 PMC: 6910174. DOI: 10.1093/jac/dkz403.

Linezolid Inhibited Synthesis of ATP in Mitochondria: Based on GC-MS Metabolomics and HPLC Method.

Ye X, Huang A, Wang X, Wen C, Hu L, Lin G Biomed Res Int. 2018; 2018:3128270.

PMID: 30410924 PMC: 6206563. DOI: 10.1155/2018/3128270.

Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.

Klupp E, Both A, Belmar Campos C, Buttner H, Konig C, Christopeit M Eur J Clin Microbiol Infect Dis. 2016; 35(12):1957-1961.

PMID: 27525679 DOI: 10.1007/s10096-016-2747-0.

References

Sullivan A, Edlund C, Nord C . Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2002; 1(2):101-14. DOI: 10.1016/S1473-3099(01)00066-4. View

Miller K, ONeill A, Wilcox M, Ingham E, Chopra I . Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother. 2008; 52(6):1940-4. PMC: 2415777. DOI: 10.1128/AAC.01302-07. View

Barbier N, Saulnier P, Chachaty E, Dumontier S, Andremont A . Random amplified polymorphic DNA typing versus pulsed-field gel electrophoresis for epidemiological typing of vancomycin-resistant enterococci. J Clin Microbiol. 1996; 34(5):1096-9. PMC: 228962. DOI: 10.1128/jcm.34.5.1096-1099.1996. View

Morales G, Picazo J, Baos E, Candel F, Arribi A, Pelaez B . Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010; 50(6):821-5. DOI: 10.1086/650574. View

Ammerlaan H, Kluytmans J, Wertheim H, Nouwen J, Bonten M . Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009; 48(7):922-30. DOI: 10.1086/597291. View

Gomez-Gil R, Romero-Gomez M, Garcia-Arias A, Gallego Ubeda M, Busselo M, Cisterna R . Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn Microbiol Infect Dis. 2009; 65(2):175-9. DOI: 10.1016/j.diagmicrobio.2009.06.010. View

Perl T, Cullen J, Wenzel R, Zimmerman M, Pfaller M, Sheppard D . Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002; 346(24):1871-7. DOI: 10.1056/NEJMoa003069. View

Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S . Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis. 2009; 200(3):390-8. PMC: 2933399. DOI: 10.1086/600122. View

Bourgeois-Nicolaos N, Moubareck C, Mangeney N, Butel M, Doucet-Populaire F . Comparative study of vanA gene transfer from Enterococcus faecium to Enterococcus faecalis and to Enterococcus faecium in the intestine of mice. FEMS Microbiol Lett. 2006; 254(1):27-33. DOI: 10.1111/j.1574-6968.2005.00004.x. View

10.

Miller K, Dunsmore C, Fishwick C, Chopra I . Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob Agents Chemother. 2008; 52(5):1737-42. PMC: 2346621. DOI: 10.1128/AAC.01015-07. View

11.

Pillai S, Sakoulas G, Wennersten C, Eliopoulos G, Moellering Jr R, Ferraro M . Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis. 2002; 186(11):1603-7. DOI: 10.1086/345368. View

12.

Prystowsky J, Siddiqui F, Chosay J, Shinabarger D, Millichap J, Peterson L . Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2001; 45(7):2154-6. PMC: 90620. DOI: 10.1128/AAC.45.7.2154-2156.2001. View

13.

McGee B, Dietze R, Hadad D, Molino L, Maciel E, Boom W . Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2009; 53(9):3981-4. PMC: 2737850. DOI: 10.1128/AAC.01378-08. View

14.

Carlet J . The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control. 2012; 1(1):39. PMC: 3554492. DOI: 10.1186/2047-2994-1-39. View

15.

Hayman S, Wilson A, Singer M, Bellingan G . Effect of linezolid and teicoplanin on skin staphylococci. J Antimicrob Chemother. 2007; 59(6):1281-2. DOI: 10.1093/jac/dkm093. View

16.

Ntokou E, Stathopoulos C, Kristo I, Dimitroulia E, Labrou M, Vasdeki A . Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2012; 67(8):1819-23. DOI: 10.1093/jac/dks146. View

17.

Bourgeois-Nicolaos N, Massias L, Couson B, Butel M, Andremont A, Doucet-Populaire F . Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. J Infect Dis. 2007; 195(10):1480-8. DOI: 10.1086/513876. View

18.

Louie A, Heine H, VanScoy B, Eichas A, Files K, Fikes S . Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother. 2010; 55(2):822-30. PMC: 3028806. DOI: 10.1128/AAC.00818-10. View

19.

Kehrenberg C, Schwarz S . Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother. 2006; 50(4):1156-63. PMC: 1426988. DOI: 10.1128/AAC.50.4.1156-1163.2006. View

20.

Welshman I, Sisson T, Jungbluth G, Stalker D, Hopkins N . Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001; 22(3):91-7. DOI: 10.1002/bdd.255. View